With one of the relatively newer but important anti-diabetic drugs, Vildagliptin manufactured by Novartis, losing patent protection in December, dozens of companies are readying plans to launch the generic version to get a slice of the action in the growing Rs 13,000-crore diabetes therapy. The cost of therapy is expected to reduce by over 50%.
from India News | Latest News Headlines & Live Updates from India - Times of India https://ift.tt/30VklKU
via ATC
Wednesday 24 July 2019
July 24, 2019
MR: EDITOR
ATC ALL TIPS N CLIPS
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation.
Related Posts
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment